首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IFNK |
| Uniprot No | Q9P0W0 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 28-207aa |
| 氨基酸序列 | LDCNLLNVHLRRVTWQNLRHLSSMSNSFPVECLRENIAFELPQEFLQYTQPMKRDIKKAFYEMSLQAFNIFSQHTFKYWKERHLKQIQIGLDQQAEYLNQCLEEDKNENEDMKEMKENEMKPSEARVPQLSSLELRRYFHRIDNFLKEKKYSDCAWEIVRVEIRRCLYYFYKFTALFRRK |
| 预测分子量 | 35.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于IFN-κ(干扰素κ)重组蛋白的参考文献示例，基于假设性研究整理：
---
1. **文献名称**: "Production and Characterization of Recombinant Human Interferon Kappa in Mammalian Cells"
**作者**: Smith J, et al.
**摘要**: 本研究在HEK293细胞中成功表达并纯化重组人IFN-κ，证实其通过激活JAK-STAT信号通路显著抑制疱疹病毒的复制，为抗病毒治疗提供新策略。
2. **文献名称**: "Recombinant IFN-κ Exerts Immunomodulatory Effects in a Murine Model of Autoimmune Encephalomyelitis"
**作者**: Lee S, et al.
**摘要**: 通过动物模型证明重组IFN-κ可调节Th17细胞分化，减轻自身免疫性脑脊髓炎炎症反应，提示其在治疗多发性硬化等疾病中的潜力。
3. **文献名称**: "Structural and Functional Analysis of Engineered IFN-κ Variants with Enhanced Stability"
**作者**: Zhang Y, et al.
**摘要**: 利用定点突变技术提高重组IFN-κ的热稳定性与血浆半衰期，同时保留其体外抗病毒活性，为药物开发提供改良方案。
4. **文献名称**: "Comparative Antiviral Activity of Type I Interferons: IFN-κ as a Potent Inhibitor of Respiratory Viruses"
**作者**: Garcia-Rivera D, et al.
**摘要**: 对比I型干扰素家族成员，发现重组IFN-κ在呼吸道细胞中对流感病毒和RSV的抑制作用优于IFN-α/β，突显其组织特异性优势。
---
**注意**：以上文献为示例性内容，实际引用时需通过学术数据库(如PubMed、Web of Science)检索真实存在的文献，并核对作者、标题及摘要准确性。若检索结果有限，建议确认术语“IFNK”是否指代IFN-κ或其他蛋白，或考虑扩大关键词范围(如“recombinant interferon kappa”)。
Interferon-kappa (IFN-κ), a member of the type I interferon family, is a cytokine with roles in innate immunity and antiviral defense. Discovered in 2001. IFN-κ shares structural homology with other type I interferons, such as IFN-α and IFN-β, but exhibits distinct expression patterns and regulatory mechanisms. It is primarily produced by epithelial cells, particularly keratinocytes, and is constitutively expressed in the skin, suggesting a specialized role in mucosal and cutaneous immunity. IFN-κ signals through the heterodimeric IFN-α/β receptor (IFNAR1/IFNAR2), activating JAK-STAT pathways to induce interferon-stimulated genes (ISGs) that mediate antiviral, antiproliferative, and immunomodulatory effects.
Recombinant IFN-κ (rIFN-κ) is produced via genetic engineering in expression systems like *E. coli* or mammalian cells. Its recombinant form retains bioactivity while enabling scalable production for research and therapeutic applications. Studies highlight IFN-κ’s unique regulatory features, including its lower induction by viral pathogens compared to other interferons and its potential role in maintaining immune homeostasis in barrier tissues. This property has spurred interest in its therapeutic potential for inflammatory skin disorders, such as psoriasis and atopic dermatitis, where dysregulated interferon responses contribute to pathogenesis.
Research also explores rIFN-κ’s antiviral efficacy against viruses like herpes simplex virus (HSV) and Zika virus, leveraging its ability to prime epithelial defenses without excessive inflammation. Additionally, its role in cancer immunotherapy is under investigation, given its capacity to modulate immune cell activity and tumor microenvironments. Challenges remain in optimizing delivery, stability, and minimizing systemic side effects. Overall, IFN-κ represents a promising yet understudied cytokine, bridging innate immunity and tissue-specific immune regulation, with recombinant technologies unlocking avenues for targeted therapeutic development.
×
